ArticleFrontiers in genetics2026
Multi-omics integration identifies ARID1B linking cuproptosis-immune crosstalk with atherosclerotic plaque progression.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerosis is a long-term inflammatory disorder of the arterial wall, characterized by lipid deposition and infiltration of immune cells. Recent studies suggest that cuproptosis may participate in the progression of atherosclerosis. Methods: Multiple scRNA-seq and bulk RNA-seq datasets were integrated to systematically characterize cuproptosis patterns in atherosclerosis. Differential expression analysis based on cuproptosis scores identified cuproptosis-modulating genes, which were further refined using least absolute shrinkage and selection operator, decision tree, and XGBoost algorithms. CellChat analysis explored the effect of ARID1B expression on intercellular communication, while immune infiltration patterns were assessed via single-sample gene set enrichment analysis. ApoE Results: Cuproptosis activity was significantly elevated in atherosclerotic tissues compared with normal arteries, with macrophages exhibiting the highest cuproptosis scores. Distinct expression profiles of cuproptosis-related genes, together with divergent immune infiltration landscapes, were observed between the high and low cuproptosis score atherosclerosis groups. ARID1B was identified as a gene discriminating cuproptosis status in atherosclerosis pathology, with significantly reduced expression in the disease group. Functional enrichment analyses suggested that ARID1B-associated networks were mainly involved in immune cell adhesion, activation, and differentiation. Conclusion: Cuproptosis-related gene ARID1B may reshape immune infiltration patterns in atherosclerosis, positioning it as a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.